Alia Therapeutics

Overview
News
Human Gene Editing?
Product stageSegments
Seed
?
R&D therapies: CRISPR/Cas9 technology
?

Italian biotech startup Alia Therapeutics, founded in October 2018, is a spin-off of the University of Trento. The company focuses on R&D of  therapeutic approaches based on gene-editing techniques for incurable genetic diseases. 

The company's main discovery is a genome-editing tool called “evo-Cas9,” which was found using yeast screening. The company has a non-exclusive license for this technology with Intellia Therapeutics. 

The company also addresses autosomal dominant disorders by focusing on single nucleotide polymorphisms (SNPs) and specific alleles, regardless of the underlying genetic mutations. 

Funding and financials 

In April 2023, the company raised EUR 4.4 million (USD 4.7 million) in a seed funding round led by Sofinnova Partners. The funds were used to strengthen Alia's gene-editing technology and support the company's expansion.

HQ location:
Piazza Vicenza, 8 Trento ITA
Founded year:
2018
Employees:
1-10
IPO status:
Private
Total funding:
USD 6.3 mn
Last Funding:
USD 4.8 mn (Seed; Apr 2023)
Last valuation:
USD 10.0 mn (Apr 2023)
Key competitors
Filter by the segments to which the disruptor belongs
All Segmentsexpand
 
Loading...
Loading...
Loading...
Loading...
Product Overview
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Product Metrics
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Company profile
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Funding data are powered by Crunchbase
arrow
menuarrow
Click here to learn more
Get a demo

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.